NL-Funded Project
Abbreviation:
Cancer-ID
Title:
New technology for monitoring Cancer therapy through extracellular vesicle IDentity.
In short:
Developing technology platform for detection and detailed molecular characterization of cancer-associated extracellular vesicles.
Tags:
Diagnostics, Human R&D, Innovation
Project Details
Funding scheme:
Technology Foundation STW – Grant ID P13-03
Time frame:
1 April 2015 to 31 December 2020
Description:
The aim of the program is to develop novel technology for monitoring cancer therapy through revealing the extracellular vesicle (EVs) identity. To that end, the project sets out to develop and validate novel technology platforms for detection and detailed molecular characterization of cancer-associated EVs. These platforms, in turn, would enable personalized medicine by efficiently monitoring disease development and therapeutic effectiveness, which will improve health care efficacy and reduce costs and, ultimately, improve the quality of life of patients. GenomeScan is leading Next Generation Sequencing efforts, performing both RNA and small RNA sequencing, thereby contributing to characterizing the molecular signature of cancer-related EVs.
Output:
T.b.a. (ongoing project)
Acknowledgements:
This work is funded by the Technology Foundation STW, with a project number P13-03.
